Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Neurodegenerative Diseases
  • Location: Europe

Abstract

FP7 gen CMYKINMiND Logo 1The goal of the Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND) consortium is to identify novel biological targets of neuroinflammation for diagnostic and therapeutic purposes and to translate this knowledge into clinical application and patient benefit. INMiND supports collaborative research on molecular mechanisms that link neuroinflammation with neurodegeneration.

Mission

INMiND’s goal is to carry out collaborative research on molecular mechanisms that link neuroinflammation with neurodegeneration in order to identify novel biological targets for activated microglia, which may serve diagnostic and therapeutic purposes, and to translate this knowledge into the clinic. Its main aims are as follows:

Financing

INMiND receives funding from the European Union’s Seventh Framework Programme, via Project No. 278850. The European Commission’s contribution is €12.0 million.

Sponsors & Partners

European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
48149 Münster
phone: +49 251 83 49300
fax: +49 251 83 49313
email: inmind@uni-muenster.de


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.